We describe a fatal case of invasive pulmonary aspergillosis in a patient with rheumatoid arthritis receiving the TNF-α inhibitor, adalimumab. The use of TNF-α inhibitor has been associated with an increased risk of infections, including tuberculosis and other opportunistic infections. Physicians should have a high index of suspicion for opportunistic infection that can develop during TNF-α inhibitor treatment.
Introduction
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease. It has been recognized that an excessive production of the inflammatory cytokines such as, tumor necrosis factor alpha (TNF-α) cause synovitis and joint destruction (1) .
Currently, three kinds of TNF-α inhibitors have been used for the treatment of RA: infliximab, etanercept, and adalimumab. These agents are reducing inflammatory disease activity and slowing radiographic progression (2, 3) . TNF-α is not only a major mediator of inflammation but also an integral part of normal defense response against infection. It is involved in apoptosis, cell activation, induction of other inflammatory cytokines, and recruitment of inflammatory cells to site of infection (1) . Patients treated with TNF-α inhibitor show a decreased production of interferon-γ and decreased expression of Toll-like receptor-4 (TLR-4), which is necessary for the recognition of microorganisms by phagocytes and dendritic cells (2) . Therefore, the use of TNF-α inhibitor is anticipated to increase susceptibility to bacterial or fungal pathogens (4, 5) . Both opportunistic and bacterial infections have been described. Few cases of fungal infections complicating such therapy have been reported in Korea (6) (7) (8) .
We describe the development of invasive pulmonary aspergillosis in a patient with RA after treatment of TNF-α inhibitor, adalimumab. She died from progressive respiratory failure and septic shock despite of anti-fungal treatment and intensive care.
Case Report
A 66-year-old woman with seropositive RA presented with productive cough and malaise for 2 weeks. She had suffered from RA for 3 years with recurrent flares of polyarthritis involving hands, wrists, and knees. During the course of disease, she underwent trials of multiple different disease modifying anti-rheumatic drugs (DMARDs) including hydroxychloroquine, sulfasalazine, leflunomide, cyclosporine, and methotrexate with limited improvement. Two months earlier, adalimumab (40 mg subcutaneous every other week) was added to her medication of celecoxib (400 mg/day), prednisolone Besides of these factors, concomitant use of immunosuppressive agents, such as corticosteroids seems to be an additional role in development of infection.
TNF-α is a central mediator in inflammation and immunity.
Specifically, TNF-α appears to have important roles in the formation and maintenance of granuloma, the migration and maturation of inflammatory cells to the site of infection, and the production of cytokines and adhesion molecules (1) . TNF-α is also involved in maintaining a T-helper cell type 1 immune response, it induces production of fungicidal interferon-γ.
Interferon γ is crucial for proper activation of phagocytosis and killing of intracellular pathogens. Pulmonary alveolar macrophages are a major defense against fungal invasion.
TNF-α appears to enhance alveolar macrophage phagocytosis of fungus and oxygen production with subsequent hyphae damage by neutrophils (12) .
Aspergillus is a saprophytic ubiquitous environmental fungus 
Summary
We describe a fatal case of invasive pulmonary aspergillosis in a patient with RA receiving TNF-α inhibitor, adalimumab.
The use of TNF-α inhibitor has been associated with an increased risk of infection such as, tuberculosis and other opportunistic infections. Physicians should have a high index of suspicion for opportunistic infection that can develop during TNF-α inhibitor treatment.
